EBGLYSS
(Lebrikizumab)Phase 3Monoclonal antibody
Eli LillyEBGLYSS is a monoclonal antibody that works as a IL-13 Inhibitor.[2] It is being investigated across 12 indications, with its most advanced program in Phase 3.[1]
EBGLYSS is one of 284 monoclonal antibody programs targeting Atopic Eczema. It is currently in Phase 3.
12
Indications
44
Total Trials
12
Active Trials
283
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1EBGLYSS
Eli LillyPhase 3
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Aciphex
Akero TherapeuticsPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
DUPIXENT
RegeneronPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Lexapro
SShirley Ryan AbilityLab
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis23 trials
Show 20 more trials
Asthma10 trials
Show 7 more trials
Airway obstruction1 trial
7 more indications
Tics1 trial
Chronic Obstructive Pulmonary Disease1 trial
CAR1 trial
Idiopathic Pulmonary Fibrosis1 trial
ART1 trial
Regulatory
FDA Approval Timeline[4]
Sep 13, 2024
EBGLYSS
BLA BLA761306
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lebrikizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]